Bengaluru, Karnataka, India: November 29, 2024:
Biocon Limited, an innovation-led global biopharmaceuticals company, proudly marked its 46th Founder’s Day with a series of inspiring and unifying events that celebrated its legacy, purpose, and vision for the future.
The celebrations began with the unveiling of the Biocon Anthem, a heartfelt composition brought to life by the talent and passion of over 500 Bioconites from across the globe. The anthem, composed by Grammy Award winner Ricky Kej, embodies Biocon’s unwavering commitment to innovation, excellence, and creating a healthier world.
This was followed by the kick-off of the John Shaw Walkathon: 10 Million Steps for Cancer by Biocon Group Chairperson Kiran Mazumdar-Shaw, held at Biocon Park. Starting with a solemn flag-off at the John Shaw Memorial Tree, this walkathon symbolized Biocon’s dedication to advancing treatments for cancer and improving patient outcomes. Employees joined hands in a powerful display of unity, walking towards a shared goal of making a meaningful impact on global healthcare.
Speaking on the occasion, Kiran Mazumdar-Shaw said: “On this special occasion of Biocon’s 46th Founder’s Day, I take immense pride in celebrating our journey as a team that has consistently strived to not just transforming healthcare but also contributing meaningfully to nation-building. When I founded Biocon, one of my goals was to prevent brain drain and create meaningful opportunities within India. Today, that vision has come to life as we have built a global brand recognized for excellence in research, world-class manufacturing, and providing affordable access to life-saving medicines. Team Biocon is more than a workplace; it’s a community that works together, dreams together, and succeeds together. Today, let us reaffirm our commitment to continue making a difference to global health, touch patients’ lives, and create a healthier planet for all.”
Ms Mazumdar-Shaw also inaugurated the Biocon Experience Center dedicated to the Late John Shaw, former Vice Chairman of Biocon Group, who played a very important role in building the Company, ensuring the highest levels of corporate governance, as well as contributing to the financial and strategic development of the Group.
The seventh edition of the Utkarsh Leadership Talk Series was also organized to mark this special day. Biocon welcomed Mr K.N. Radhakrishnan, Director and CEO of TVS Motor Company, who delivered an inspiring talk on “Elevating Excellence.” The Utkarsh Talk Series, organized by the Biocon Group Centre of Operational Excellence (CoE), reaffirms the commitment to fostering a culture of continuous improvement through the John Shaw Excellence Model (JSEM), which enables the Group’s strategic business units to compete for the annual John Shaw Excellence Awards.
Reflecting on its 46-year journey, Biocon celebrates its evolution into a diversified biopharmaceutical enterprise dedicated to addressing global health disparities through affordable innovation. Biocon remains steadfast in its mission to create exponential and enduring value for stakeholders while improving the lives of millions of patients worldwide.
The energy, enthusiasm, and collective pride showcased during the Founder’s Day celebrations highlight the spirit of Biocon’s global family as it continues its journey of transforming healthcare and inspiring excellence.
About Biocon Limited:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on X ( formerly Twitter) @bioconlimited and LinkedIn: Biocon Limited for company updates.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.
Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates.
Download Press Release
